×
About 12,886 results

ALLMedicine™ Myelodysplastic Syndromes Center

Research & Reviews  6,131 results

Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells.
https://doi.org/10.1097/MOH.0000000000000620
Current Opinion in Hematology; Doulatov S, Papapetrou EP

Dec 2nd, 2020 - Myeloid malignancies comprise a spectrum of genetically heterogeneous disorders marked by the stepwise acquisition of somatic mutations and clonal evolution. The blood and bone marrow of patients typically consists of a mix of different clones and...

Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate ...
https://doi.org/10.3324/haematol.2020.249995
Haematologica Alana Vicente , Bhavisha A Patel et. al.

Dec 1st, 2020 - Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders characterized by cytopenia and a propensity to develop acute myeloid leukemia (AML). The management of lower-risk (LR) MDS with persistent cytopenias remains suboptimal. Eltro...

The expression levels of long non-coding RNA KIAA0125 are associated with distinct clin...
https://doi.org/10.1111/bjh.17231
British Journal of Haematology References; Hung SY, Lin CC et. al.

Nov 29th, 2020 - Long non-coding RNAs (lncRNAs) have important functions in cancer biology. Among them, lncRNA KIAA0125 is one of the genes proposed to play a critical role in leukaemia stem cell (LSC). In this study, we aimed to investigate the clinical relevance...

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment a...
https://doi.org/10.1016/j.annonc.2020.11.002
Annals of Oncology : Official Journal of the European Society for Medical Oncology; Fenaux P, Haase D et. al.

Nov 22nd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|

Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mu...
https://doi.org/10.1111/ijlh.13400
International Journal of Laboratory Hematology REFERENCES; Patel JL, Abedi M et. al.

Nov 21st, 2020 - The presence of ring sideroblasts (RS) and mutation of the SF3B1 gene are diagnostic of lower-risk (LR) myelodysplastic syndromes (MDS) and are correlated with favorable outcomes. However, information on testing and reporting in community-based cl...

see more →

Guidelines  31 results

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment a...
https://doi.org/10.1016/j.annonc.2020.11.002
Annals of Oncology : Official Journal of the European Society for Medical Oncology; Fenaux P, Haase D et. al.

Nov 22nd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|

Considerable Variation Exists in Receipt of Complete Diagnostic Evaluations for Myelodysplastic Syndromes Among Medicare Patients
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/

May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).

Hematology Quality Metrics
http://www.hematology.org/Clinicians/Guidelines-Quality/503.aspx
Allen, S.

Feb 20th, 2018 - These clinical performance measures are designed for individual quality improvement. Some of the measures may also be appropriate for accountability if appropriate sample sizes and implementation rules are achieved.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0007
Journal of the National Comprehensive Cancer Network : JNCCN; Greenberg PL, Stone RM et. al.

Jan 3rd, 2017 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the p...

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from...
http://www.bloodjournal.org/content/122/17/2943
Malcovati, L.,et al.

Oct 23rd, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit.

see more →

Drugs  55 results see all →

Clinicaltrials.gov  6,375 results

Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells.
https://doi.org/10.1097/MOH.0000000000000620
Current Opinion in Hematology; Doulatov S, Papapetrou EP

Dec 2nd, 2020 - Myeloid malignancies comprise a spectrum of genetically heterogeneous disorders marked by the stepwise acquisition of somatic mutations and clonal evolution. The blood and bone marrow of patients typically consists of a mix of different clones and...

Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate ...
https://doi.org/10.3324/haematol.2020.249995
Haematologica Alana Vicente , Bhavisha A Patel et. al.

Dec 1st, 2020 - Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders characterized by cytopenia and a propensity to develop acute myeloid leukemia (AML). The management of lower-risk (LR) MDS with persistent cytopenias remains suboptimal. Eltro...

The expression levels of long non-coding RNA KIAA0125 are associated with distinct clin...
https://doi.org/10.1111/bjh.17231
British Journal of Haematology References; Hung SY, Lin CC et. al.

Nov 29th, 2020 - Long non-coding RNAs (lncRNAs) have important functions in cancer biology. Among them, lncRNA KIAA0125 is one of the genes proposed to play a critical role in leukaemia stem cell (LSC). In this study, we aimed to investigate the clinical relevance...

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment a...
https://doi.org/10.1016/j.annonc.2020.11.002
Annals of Oncology : Official Journal of the European Society for Medical Oncology; Fenaux P, Haase D et. al.

Nov 22nd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|

Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mu...
https://doi.org/10.1111/ijlh.13400
International Journal of Laboratory Hematology REFERENCES; Patel JL, Abedi M et. al.

Nov 21st, 2020 - The presence of ring sideroblasts (RS) and mutation of the SF3B1 gene are diagnostic of lower-risk (LR) myelodysplastic syndromes (MDS) and are correlated with favorable outcomes. However, information on testing and reporting in community-based cl...

see more →

News  285 results

FDA Approves Oral Therapy for Myelodysplastic Syndromes, CMML
https://www.medscape.com/viewarticle/933602

Jul 7th, 2020 - The Food and Drug Administration has approved Inqovi (decitabine and cedazuridine tablets, Astex Pharmaceuticals) to treat adults with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The agency's action gives physicians ...

Considerable Variation Exists in Receipt of Complete Diagnostic Evaluations for Myelodysplastic Syndromes Among Medicare Patients
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/

May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).

First Advance in MDS for Decade: Luspatercept for Anemia
https://www.medscape.com/viewarticle/928198

Apr 5th, 2020 - The US Food and Drug Administration (FDA) has approved luspatercept (Reblozyl, Bristol-Myers Squibb/Acceleron) for the treatment of anemia in patients with myelodysplastic syndromes (MDS). The green light represents the first treatment advancement...

Drug Reduces Need for Transfusions in Some Patients With Myelodysplastic Syndromes
https://www.medscape.com/viewarticle/923569

Jan 9th, 2020 - (Reuters Health) - Therapy every 3 weeks with the drug luspatercept dramatically reduced the need for blood transfusions in a subset of patients with lower-risk myelodysplastic syndromes (MDS), according to results from the MEDALIST study reported...

Genetic analysis highlights value of germline variants in MDS, AML
https://www.mdedge.com/hematology-oncology/article/208332/aml/genetic-analysis-highlights-value-germline-variants-mds-aml?channel=39313
Caleb Rans

Sep 18th, 2019 - Germline DDX41 mutations were found to be relatively prevalent and showed favorable outcomes in a cohort of patients with myelodysplastic syndromes or acute myeloid leukemia, according to a genetic analysis. Jezperklauzen/ThinkStock The results de.

see more →

Patient Education  9 results see all →